Eficacia y seguridad del infliximab a largo plazo (5 años) en pacientes con enfermedad de Crohn
XXVI Reunión de la Sociedad Gallega de Patología Digestiva
Lugo 25 y 26 noviembre 2011
Comunicaciones
Eficacia y seguridad del infliximab a largo plazo (5 años) en pacientes con enfermedad de Crohn
Semana de las Enfermedades Digestivas.
Sevilla11-14 de junio 2011
Rev Esp Enferm Dig 2011; 103 (Suplemento I):133
Nuevas asociaciones genéticas detectadas en un estudio de asociación de exoma completo de la toxicidad relacionada con el tratamiento tiopurínico en la enfermedad inflamatoria intestinal
XIV Reunión Nacional de la Asociación Española de Gastroenterología
Madrid 23-25 Marzo 2011
Gastroenterología y Hepatología 2011; 34 (3):205.
Long-term (5 years) efficacy and safety of infliximab in Crohn´s disease patients
ECCO 2012 Barcelona
Long-term (5 years) efficacy and safety of infliximab in Crohn´s disease patients
19th UEGW
Stockolm 22-26
October 2011Gut 2011; 60 (Suppl III): A-192
New Genetic Associations Detected in an Exome-Wide Association Study for Toxicity Related to Thiopurine Treatments in Inflammatory Bowel Disease
Digestive Disease week 2011
Chicago 7-10 mayo 2011
Gastroenterology 2011:140(5) Supp 1,S-271
Pharmacogenetics study of TPMT and ITPA genes in patients with inflammatory bowel disease treated with azathioprine detects relation between ITPase deficiency and clinical response
Digestive Disease week 2011
Chicago 7-10 mayo 2011
Gastroenterology 2011:140(5) Supp 1,S-769.
Premio al mejor póster de su categoría
Pharmacogenetics study of TPMT and ITPA genes in patients with inflammatory bowel disease treated with azathioprine detects relation between ITPase deficiency and clinical response
6th ECCO Congress.
Dublin, Ireland, February 24-26 2011
Journal of Crohn´s & colitis 2011;5(1):s-161
Candidate genes for azathioprine’s efficacy or toxicity in inflammatory bowel disease patients using a exome-wide genotyping analysis
6th ECCO Congress.
Dublin, Ireland, February 24-26 2011
Journal of Crohn´s & colitis 2011;5(1):s-160
Use of adalimumab in anti-TNF naive Crohn’s disease patients: Clinical experience in a multicenter cohort”
6th ECCO Congress.
Dublin, Ireland, February 24-26 2011
Journal of Crohn´s & colitis 2011;5(1):s-106
Influence of rural/urban environment severity of Inflammatory Bowel Disease
Barreiro M, Echarri A, Pereira S, Carpio D, Castro J, Ferreiro R, Alvarez V, Lorenzo A.
Digestive Disease Week and the 109th Annual Meeting of the AGA Institute.
San Diego 17-22 may 2008.
Gastroenterology 2008; 134 (4) A-504
Influence of environmental factors in the severity of Inflammatory Bowel Disease?
Barreiro M, Carpio D, Echarri A, Pereira S, Martinez-Ares D, Lorenzo A, Alvarez V, Castro J.
Digestive Disease Week and the 110th Annual Meeting of the AGA
Institute. Chicago 30 mayo- 4 junio 2009
Gastroenterology 2009; 136 (5) A-356
Influence of rural/urban environment severity of Inflammatory Bowel Disease in patients from coastal versus non-coastal towns.
Carpio D, Echarri A, Barreiro M, Pereira S, Alvarez V, Ferreiro R, Lorenzo A, Castro J.
Digestive Disease Week and the 109th Annual Meeting of the AGA Institute.
San Diego 17-22 may 2008Gastroenterology 2008; 134 (4) A-505
Influence of rural/urban environment severity of Inflammatory Bowel Disease in patients from coastal versus non-coastal towns.
Barreiro M, Echarri A, Carpio D, Pereira S, Castro J, Ferreiro R, Alvarez V, Lorenzo A.
Digestive Disease Week and the 109th Annual Meeting of the AGA Institute.
San Diego 17-22 may 2008.
Gastroenterology 2008; 134 (4) A-504
Influence of rural/urban environment severity of Inflammatory Bowel Disease
Barreiro M, Echarri A, Pereira S, Carpio D, Castro J, Ferreiro R, Alvarez V, Lorenzo A.
3rd ECCO Congress
Lyon, France February 28-March 1 2008
Journal of Crohn´s & colitis 2008;2(1):72